OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2017
(3)
2016
(2)
2024
(1)
2018
(1)
2013
(1)
2012
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry.
Not available
S-EPMC3936790
|
biostudies-literature
Cite
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
Not available
S-EPMC6002964
|
biostudies-literature
Cite
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
Not available
S-EPMC4856174
|
biostudies-literature
Cite
Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry.
Not available
S-EPMC3908898
|
biostudies-literature
Cite
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Not available
S-EPMC9849915
|
biostudies-literature
Cite
Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial.
Not available
S-EPMC10924708
|
biostudies-literature
Cite
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Not available
S-EPMC5731244
|
biostudies-literature
Cite
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Not available
S-EPMC4985288
|
biostudies-literature
Cite
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Not available
S-EPMC9792409
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets